Aug 2026· Phytotherapy Research· 0 citations· 34 references
Medicine
TL;DR
XSBO alleviates AD-related cognitive impairment and neuroinflammation by modulating the gut microbiota-SCFA axis and inhibiting TLR4/MyD88/MAPK-mediated inflammatory responses, and suggest that XSBO may serve as a promising dietary intervention for neurodegenerative disease management.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with cognitive decline and neuroinflammation. Xanthoceras sorbifolia Bunge oil (XSBO), a woody plant oil rich in bioactive fatty acids, has shown potential health benefits. This study aimed to investigate the neuroprotective effects and underlying mechanisms of XSBO in AD. A scopolamine-induced AD rat model was established to evaluate the effects of XSBO on cognitive function, pathological changes, and neuroinflammation. Gut microbiota alterations were analyzed by 16S rDNA sequencing. Fecal microbiota transplantation (FMT) and short-chain fatty acid (SCFA) supplementation experiments were performed to explore the role of gut microbiota-derived metabolites. The TLR4/MyD88/MAPK signaling pathway was further examined. XSBO treatment improved cognitive deficits, reduced neuronal damage and neuroinflammation, and enhanced intestinal barrier integrity in AD rats. XSBO restored gut microbiota dysbiosis and increased SCFA-producing bacteria. FMT and SCFA supplementation confirmed that microbiota-derived metabolites contributed to XSBO-mediated cognitive improvement and neuroprotection. Mechanistically, XSBO inhibited lipopolysaccharide-induced neuroinflammation by suppressing TLR4/MyD88/MAPK signaling activation. XSBO alleviates AD-related cognitive impairment and neuroinflammation by modulating the gut microbiota-SCFA axis and inhibiting TLR4/MyD88/MAPK-mediated inflammatory responses. These findings suggest that XSBO may serve as a promising dietary intervention for neurodegenerative disease management.
Findings demonstrate that APS alleviates cognitive deficits and AD-like pathology, partially through remodeling gut microbiota and modulating the gut-brain axis, and represents a promising natural compound-based therapeutic candidate for managing cognitive decline associated with Alzheimer’s disease.
Xiaolin Cui, Zhen Wei, Qingshui Wang et al.· Frontiers in Pharmacology· 0 citations
Emerging evidence implicates gut microbiota dysbiosis in Alzheimer's disease (AD) pathogenesis, suggesting probiotic interventions as a viable therapeutic strategy. This study systematically screened 18 Bifidobacterium strains, among which Bifidobacterium breve LE4 exhibited both potent antioxidant activity and lip...
Liu Yang, Yu-Tian Huang, Meng-Ling Chen et al.· Food Science and Human Welln...· 0 citations
Disruptions along the brain-gut-microbiota axis significantly contribute to Alzheimer's disease (AD) pathogenesis. This study evaluated the therapeutic potential of a multi-strain probiotic mixture in mitigating cognitive decline, neuroinflammation, and amyloid pathology in an AD rat model. In the present study, after...
Asmaa M. Elfiky, Eman M. Shahy, A. Mahmoud· Physiology and Behavior· 0 citations
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited disease-modifying therapies. Chronic aluminum exposure, a well-recognized environmental risk factor, exacerbates AD pathogenesis by driving oxidative stress and neuroinflammation. Schisandrin A (SchA), a bioactive lignan from the medicina...
Jingping Xue, Minhong Niu, Xiao-Yu Song et al.· Nutritional neuroscience· 0 citations
Delayed neurocognitive recovery (dNCR) is the most common complication after anesthesia and surgery (A/S) with unclear mechanisms and no effective therapy. Here, we purified a pectin polysaccharide (GP) from guava fruits (Mw 94.516 kDa), featuring a backbone of HG and RG-I domains with side chains of →3,6)-β-d-Galp-(1→...
Qin Gao, Yi-Xuan Chen, P. Yu et al.· Journal of Agricultural and...· 0 citations
The gut microbiota acts as an upstream regulator of AD pathology through interconnected molecular mechanisms, and microbiota-targeted interventions have the potential to modulate these pathways and improve cognitive outcomes, although results vary across studies.
Javeria Fatima, Y. Siddique· CNS and Neurological Disorde...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.